GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » NexgenRx Inc (TSXV:NXG) » Definitions » EV-to-EBITDA

NexgenRx (TSXV:NXG) EV-to-EBITDA : 15.26 (As of May. 03, 2024)


View and export this data going back to 2006. Start your Free Trial

What is NexgenRx EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NexgenRx's enterprise value is C$15.75 Mil. NexgenRx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$1.03 Mil. Therefore, NexgenRx's EV-to-EBITDA for today is 15.26.

The historical rank and industry rank for NexgenRx's EV-to-EBITDA or its related term are showing as below:

TSXV:NXG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -185.44   Med: 9.14   Max: 304.3
Current: 15.26

During the past 13 years, the highest EV-to-EBITDA of NexgenRx was 304.30. The lowest was -185.44. And the median was 9.14.

TSXV:NXG's EV-to-EBITDA is ranked worse than
86.67% of 15 companies
in the Healthcare Plans industry
Industry Median: 8.25 vs TSXV:NXG: 15.26

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), NexgenRx's stock price is C$0.22. NexgenRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.003. Therefore, NexgenRx's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


NexgenRx EV-to-EBITDA Historical Data

The historical data trend for NexgenRx's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexgenRx EV-to-EBITDA Chart

NexgenRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.52 6.42 8.20 12.13 15.28

NexgenRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.13 15.04 18.17 15.95 15.28

Competitive Comparison of NexgenRx's EV-to-EBITDA

For the Healthcare Plans subindustry, NexgenRx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexgenRx's EV-to-EBITDA Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, NexgenRx's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NexgenRx's EV-to-EBITDA falls into.



NexgenRx EV-to-EBITDA Calculation

NexgenRx's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15.752/1.032
=15.26

NexgenRx's current Enterprise Value is C$15.75 Mil.
NexgenRx's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NexgenRx  (TSXV:NXG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NexgenRx's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.22/-0.003
=At Loss

NexgenRx's share price for today is C$0.22.
NexgenRx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


NexgenRx EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NexgenRx's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


NexgenRx (TSXV:NXG) Business Description

Traded in Other Exchanges
Address
191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and provides ancillary services. Some of the products and services of the company are Dental Claims, Prescription Drug Claims and many more.